Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches

Taiwanese Journal of Obstetrics & Gynecology
Hao Lin, Chan-Chao Changchien

Abstract

Approximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum. Overall response rates are high, ranging from 70-80%; however, 70-80% of responders will relapse and require further systemic chemotherapy. Patients who experience disease relapse with platinum-free interval of less than 6 months are considered as platinum-refractory/resistant individuals. In this clinical setting, agents with non-cross-resistance to first-line therapy and favorable toxicity profiles are usually chosen. In the management of relapsed patients with platinum-free interval over 6 months, the generally accepted recommendation is retreatment with a platinum plus paclitaxel combination. In general, treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, maintaining or improving quality of life, delaying time to progression, and prolonging survival. A number of currently available and novel investigating agents in recurrent epithelial ovarian cancer will be reviewed in this context.

References

Jan 1, 1992·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·I B VergoteK Nustad
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·T C ChouS J Danishefsky
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurie MarkmanMark Baker
Mar 22, 2003·Gynecologic Oncology·Giuseppe D'AgostinoIgnace Vergote
Sep 19, 2003·Gynecologic Oncology·Maurie MarkmanJerome Belinson
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T K ChoueiriR M Bukowski
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Mar 27, 2007·Gynecologic Oncology·Ernest S Han, Bradley J Monk

❮ Previous
Next ❯

Citations

Jul 28, 2011·Taiwanese Journal of Obstetrics & Gynecology·Yen-Ying MaChia-Chi Lung
Jan 13, 2009·Gynecologic Oncology·Kristy ShieldGregory E Rice
Mar 16, 2012·Future Medicinal Chemistry·Jason A WilkenNita J Maihle
Nov 6, 2020·The Journal of Medical Investigation : JMI·Dalia Abd El-Moniem ElrawiEman Naguib Khorshed

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
William E WinterGynecologic Oncology Group Study
Clinical Oncology : a Journal of the Royal College of Radiologists
A E GuppyG J S Rustin
© 2021 Meta ULC. All rights reserved